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Abstract
Background: In most endemic parts of the world, onchocerciasis (river blindness) control relies,
or will soon rely, exclusively on mass treatment with the microfilaricide ivermectin. Worldwide
eradication of the parasite by means of this drug is unlikely. Macrofilaricidal drugs are currently
being developed for human use.
Methods: We used ONCHOSIM, a microsimulation mathematical model of the dynamics of
onchocerciasis transmission, to explore the potentials of a hypothetical macrofilaricidal drug for
the elimination of onchocerciasis under different epidemiological conditions, as characterized by
previous intervention strategies, vectorial capacity and levels of coverage.
Results: With a high vector biting rate and poor coverage, a very effective macrofilaricide would
appear to have a substantially higher potential for achieving elimination of the parasite than does
ivermectin.
Conclusions: Macrofilaricides have a substantially higher potential for achieving onchocerciasis
elimination than ivermectin, but high coverage levels are still key. When these drugs become
available, onchocerciasis elimination strategies should be reconsidered. In view of the impact of
control efforts preceding the introduction of macrofilaricides on the success of elimination, it is
important to sustain current control efforts.
Background
Onchocerciasis, or river blindness, is caused by infection
with the filarial parasite Onchocerca volvulus. The para-
site is transmitted by Simulium species (blackflies) that
breed in fast flowing streams [1,2]. Until recently the
blindness and skin pathology caused by heavy infections,
constituted a major public health problem in many parts
of tropical Africa, Yemen, and Latin America. This con-
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sideration led to the establishment of the Onchocerciasis
Control Programme (OCP) [3] in West Africa, the On-
chocerciasis Elimination Program in the Americas
(OEPA) [4], and the African Program for Onchocerciasis
Control (APOC) [5,6]. All three programmes have come
to rely on the regular (OEPA semi-annually, OCP both
annually and semi-annually, and APOC annually) distri-
bution of ivermectin (Mectizan®) to lower the micro-
filarial load in affected individuals and thereby reduce
transmission and mitigate the clinical manifestations of
the infection [7]. In addition, since 1975, OCP has made
intensive use of vector control by means of aerial larvi-
ciding. This has led to the virtual elimination of the par-
asite from many formerly endemic areas. However, as
the OCP will come to an end in 2002, potential recrudes-
cence of the infection, resulting from residual foci or im-
migration of infected humans and flies, remains a
serious threat unless total elimination can be achieved
[8]. In Africa, after the cessation of larviciding, control of
the infection will rely on decentralized annual ivermectin
distribution, which has been made available by Merck
and Co. for as long as it will be needed. This has several
disadvantages. First, in view of imperfect geographical
and therapeutic coverage, and density dependence in the
microfilarial uptake by flies [9,10], low level transmis-
sion may continue. Second, resistance to ivermectin
might develop and spread [11], as it already has in some
nematode parasites of veterinary importance [12–15].
Third, in man, the average life-span of adult worms is ap-
proximately 10 years, and while repeated treatments of
ivermectin seem to have some permanent effect on the
fertility of adult worms, this effect manifests itself only
slowly after years of treatment [16].
Unfortunately, the number of safe effective alternative
treatments is limited. Diethylcarbamazine, also a micro-
filaricide, causes severe side effects in onchocercia-
sis[17]. Suramin, the only currently available highly
effective macrofilaricide has even more serious side ef-
fects [18]. Large scale nodulectomy, which has been at-
tempted in Latin America, is impractical and will never
succeed in eliminating all adult worms [19,20].
Some success was obtained with amocarzine, although
its macrofilaricidal properties were not optimal [21].
Several other compounds are currently under considera-
tion. One of these is doxycycline which following long-
term treatment was shown to sterilize adult worms in
treated humans, an effect that was correlated with the
disappearance of the filarial endosymbiont (Wolbachia
spp) [22,23]. Another promising drug, widely used in
veterinary practice, is moxidectin [24,25]. When used as
a single dose it either kills or sterilizes the adult worm de-
pending on the animal model and parasite used. The
half-life of this drug in animals is approximately 10 times
that of ivermectin, thereby reducing the probability of
successful re-infection. However, the effect of this com-
pound in humans remains to be evaluated.
The advantages of macrofilaricidal drugs are obvious.
With a 100% effective macrofilaricide and 100% cover-
age, elimination could be achieved almost instantane-
ously. By contrast, with ivermectin, even with 100%
coverage – impossible under current exclusion criteria –
elimination of the infection from the community would
take over a decade.
Even if not all adult worms were killed due to lower drug
efficacy or incomplete coverage, a macrofilaricide would
still be more effective than ivermectin alone.
Taking in consideration the above issues we will address,
by using the microsimulation ONCHOSIM model, the
possible effects of incorporating a macrofilaricidal drug
on the control of O. volvulus and provide suggestions on
how it should be best used.
Methods
Both the life cycle of the parasite and the effects of an in-
tervention are highly complex. While mathematical
models can still be formulated explicitly, model equa-
tions are impossible to solve analytically [26–28].
Stochastic microsimulation was therefore used as a nu-
merical technique to explore the potential of macrofilar-
icides. The ONCHOSIM model and computer program,
developed by Plaisier et al[29,30] was adapted to incor-
porate the effect of such a macrofilaricide. We optimisti-
cally assumed that a single dose of the drug (or drug
combination) under consideration would kill or sterilize
95% of all adult worms. We further assumed that it
would have the same effects as ivermectin on the remain-
ing worms. This could be achieved, if necessary, by com-
bining the macrofilaricide with ivermectin. We did not
make any assumption about a protective prophylactic ef-
fect on re-infection. Parameters, such as the parasite up-
take curve, validated to be appropriate for use in areas
where the savannah type (blinding) vector-parasite com-
plex dominates, were available as default settings for this
programme [30]. In all cases a 10-year programme of an-
nual macrofilariciding was considered. While longer pe-
riods may have higher success rates, in practice it may be
unrealistic to expect that control programmes can be
sustained uninterruptedly for many decades. The out-
come of interest is the probability that this 10 years pro-
gramme would lead to elimination of the parasite from a
closed community (village) of approximately 400 peo-
ple.
Three scenarios were considered for simulation.BMC Public Health 2001, 1:12 http://www.biomedcentral.com/1471-2458/1/12
1. A scenario in which the introduction of the macrofila-
ricide follows a period of 12 years of intensive control
with larviciding (achieving a conservative 65% reduction
in biting rates) and ivermectin distribution. Prevalence
and transmission have been reduced to a very low level.
This pattern is characteristic of many areas covered by
OCP. The impact of the macrofilaricide is contrasted
with a continued distribution of ivermectin (for 10
years), both in the absence of continued larviciding (i.e.
the situation as it will prevail in the OCP countries after
the OCP has been phased out).
2. A scenario in which control has been limited to 5 years
of annual ivermectin distribution. By the time macrofila-
ricides become available this will be characteristic of
many areas covered by the African Programme for On-
chocerciasis Control (APOC). Following these 5 years of
ivermectin distribution continued ivermectin distribu-
tion for 10 years is compared to its replacement with the
macrofilaricide (or a combination of the two drugs).
3. A scenario in which there has not been any control
measures for many years. This is typical for areas not
covered by either OCP or APOC. This scenario also char-
acterizes areas, such as parts of the north of Sierra Leone,
in which the programme has been suspended for many
years. The macrofilaricide is compared to the introduc-
tion of ivermectin distribution.
To adjust the level of endemicity we used the entomolog-
ical parameter "biting rate". At Asubende, a highly en-
demic area with a community microfilarial load (CMFL)
[31] of approximately 60–70 mf per skin snip, a mean
monthly biting rate of 2400 s. damnosum bites for an
adult human male has been observed. For each of these
scenarios above we considered sub-scenarios with biting
rates equal to the Asubende level, equal to 50% above
(i.e. a monthly biting rate of 3600) and equal to 50% be-
low (i.e. a biting rate of 1200) this level. Biting rates for
other types of individuals (women, children) were as-
sumed proportional to the biting rate in adult males. For
all scenarios we only considered mass treatment once
annually. Another parameter that we varied was the cov-
erage. Both a "low" coverage of 50% and a high coverage
of 75% of the total population were considered. Each
configuration was simulated a 100 times. In all cases we
assumed that groups not eligible for ivermectin treat-
ment (pregnant women, children under 5 years of age)
were neither eligible for macrofilaricide treatment. Com-
pliance was not considered to be fully random, but to de-
pend on an individual's propensity to adhere to
treatment [32]. This implies that individuals with a low
propensity to comply may act as a reservoir for the para-
site and this scenario is thus more pessimistic (especially
for macrofilaricides) than completely random adher-
ence. We ignored all forms of drug resistance. We did not
consider the effects of immigration of infected individu-
als or the influx of infected flies. This means that conclu-
sions regarding elimination of infection are only valid
when interventions are targeted at sufficiently large are-
as simultaneously and the probability of elimination in
individual communities is high.
Results
The results are shown in Table 1.
Table 1: Simulation results, using ONCHOSIM. Cells are based on 100 simulations each. Each cell shows number of eliminations ob-
tained with a macrofilaricide/number of eliminations obtained with ivermectin.
Coverage (percentage of individuals actual 
getting treatment during mass treatment)
Monthly Biting Rate Number of successful eliminations
macrofilaricide/ivermectin per 100 simulations
Scenario 1 
('OCP')
Scenario2 
('APOC')
Scenario3 (no previous intervention)
50% 1200 100/100 97/42 64/0
50% 2400 78/23 0/0 0/0
50% 3600 1/0 0/0 0/0
75% 1200 100/100 100/100 100/97
75% 2400 100/100 98/0 68/0
75% 3600 100/98 28/0 9/0BMC Public Health 2001, 1:12 http://www.biomedcentral.com/1471-2458/1/12
Discussion
Low levels of infection and transmission of onchocercia-
sis, as indicated by a low CMFL, have little public health
impact, and mild infections can go almost unnoticed. An
intervention programme that would succeed in keeping
epidemiological indices at low levels would therefore
have a public health impact similar to actual elimination
of the parasite. In the absence of the development of re-
sistance, annual ivermectin distribution with a reasona-
bly high coverage is probably totally adequate for this.
Even under conditions of continued high transmission,
ivermectin based control programs could prevent or mit-
igate most of the morbidity of onchocerciasis infections.
Yet, we have chosen elimination as our target. The rea-
son for this is that in the absence of elimination, control
measures would have to be sustained and should retain
their effectiveness. Failing these conditions, e.g. due to
the development of resistance, recrudescence to pre-in-
tervention levels may only be a matter of time.
We explored the potential of macrofilaricides to bring
about elimination. Coverage is key, as non-compliant in-
dividuals may act as reservoirs for the infection and
thereby perpetuate transmission. Obviously, macrofilar-
iciding if applied to 100% of the population – currently
unattainable – must quickly lead to elimination of the
parasite. Still, if only few individuals escape treatment,
the reservoir of infection will ultimately be depleted by
the natural mortality of the parasite, assuming that im-
migration of new L3 larvae has been interrupted. Wheth-
er a specific coverage level under specific circumstances
would achieve elimination can best be theoretically ex-
plored using microsimulation. In this study, such simu-
lations were used to explore whether elimination would
be feasible within 10 years. We made several assump-
tions that we believe reflect the limitations that actual
control programs could encounter. First, similar to iver-
mectin, children under 5 were assumed to be excluded
from treatment. Second, we assumed that treatment ad-
herence was imperfect and that some individuals have a
greater propensity to escape treatment than others.
We considered several scenarios. Our main objective was
twofold, viz. estimating the 'absolute' probability of elim-
ination of the parasite from the community, and to com-
pare this probability to that of (continued) use of
ivermectin alone. In all cases we found that a macrofila-
ricide had a substantially higher potential for achieving
elimination than ivermectin. Yet, even with a macrofila-
ricide, elimination would rarely be achieved within 10
years when treatment coverage is low and/or biting rates
are high. Control efforts prior to the introduction of the
macrofilaricide also appeared to be important: in "OCP"
areas, with highly favourable epidemiological indices at
the outset of macrofilariciding, continued use of iver-
mectin alone would also often lead to elimination. As we
only evaluated the success rates of entire programmes
(i.e. including all preceding control measures), in some
instances elimination might have been achieved even in
the absence of those extra 10 years of treatment. Outside
"OCP" areas (scenarios 2 and 3) elimination would never
be achieved by ivermectin alone within 10 (additional)
years, unless biting rates were low. By contrast, even un-
der difficult conditions of high biting rates or low cover-
age, macrofilaricide based programmes would
occasionally be successful within 10 years. If so, provided
programmes are continued for a sufficiently longer peri-
od, ultimate success would be likely.
We wish to stress that our conclusions are based on mi-
crosimulations and are therefore contingent upon the
validity of the model and the assumed properties of the
drug. Real macrofilaricides may have properties that dif-
fer from those assumed in the model. For example, the
drug may prevent re-infection for some time following
treatment (thereby enhancing its effect) or it may steri-
lize female worms but be ineffective against male adult
worms (thereby reducing its effect). Arguably, even the
most effective antihelminths (e.g. albendazole against
ascariasis) barely have our assumed 95% killing rate.
Whenever a macrofilariciding drug becomes available
for human use, extensive simulations should be carried
out to explore its potential. Nevertheless, only communi-
ty trials can demonstrate whether modelling results can
be replicated in the field.
Conclusions
Macrofilaricides have a substantially higher potential for
achieving onchocerciasis elimination than ivermectin,
but high coverage levels are still key. When these drugs
become available for human use, onchocerciasis elimina-
tion strategies should be reconsidered. In view of the im-
pact of control efforts preceding the introduction of
macrofilaricides on the success of elimination, it is im-
portant to sustain current control efforts.
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